B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL [Phase 1]
Phase 1 study evaluating CD19 CAR-T cells in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; th…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 [Phase 1]
Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of YK012 in relapsed or refractory B-…
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma [Phase 1]
This report covers the completion of a Phase 1 study evaluating the CAR-T therapy C-CAR039 in patients with relapsed or refractory B-cell no…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 study evaluating acalabrutinib plus lisocabtagene maraleucel (Liso-Cel) in refractory/relapsed aggressive B-cell lymphomas, includin…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL [Phase 1]
A Phase 1 clinical trial evaluating the XP-006 mRNA vaccine for relapsed/refractory B-cell non-Hodgkin lymphoma is listed as not yet recruit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies [Phase 1]
A Phase 1 clinical trial update for a bicistronic CAR-T cell therapy targeting CD19 and CD20 in B-cell malignancies; current status is not r…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies [Phase 1]
This clinical trial update describes a Phase 1 study evaluating fully human bispecific CAR T cells targeting CD20 and CD19 in relapsed or re…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors [Phase 2]
A Phase 2 clinical trial evaluating CAR-T therapy after autologous stem cell transplant for relapsed/refractory B-cell non-Hodgkin lymphoma …
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas [Phase 1]
This document provides an update on a Phase 1 clinical study of RN1701 Injection for relapsed/refractory B-cell non-Hodgkin lymphoma. The st…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice
A prospective observational cohort study assessing the clinical impact of novel monoclonal antibodies in B-cell non-Hodgkin lymphoma within …
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients [Phase 1]
Phase 1 study assessing safety and tolerability of CD19x22 CAR T cells in adolescents and adults with relapsed/refractory B-cell non-Hodgkin…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial is evaluating the safety and activity of SAR448501/DR-0201 in patients with relapsed or refractory B-cell non-Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: STAY-STRONG Study of Exercise Training During Chemotherapy [NA]
The STAY-STRONG study evaluating exercise training during chemotherapy in lymphoma patients has completed, examining effects on body composi…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 clinical trial update on Pemigatinib in relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell lymphoma and marg…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1]
Phase I clinical trial update for JS203 in relapsed/refractory B-cell non-Hodgkin's lymphoma, with the study listed as active but not recrui…
-
CLINICAL_TRIALS trial_result · 2025-12-01Clinical Trial Update: Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study of a CD19/CD20 dual-targeted cell therapy in relapsed or refractory B-cell non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS other · 2025-11-26Clinical Trial Update: Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies [NA]
Clinical trial update for Miltenyi Biomedicine's cell and gene therapy program indicates ongoing recruitment and planned long-term follow-up…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL [Phase 1]
Phase 1 clinical trial update on cord blood-derived IL-10/IL-15 CD19-CAR NK cells for refractory/relapsed B-cell non-Hodgkin lymphoma, curre…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies [Phase 1]
A Phase 1 clinical trial of an in vivo CAR-T therapy for relapsed/refractory hematologic cancers is currently recruiting. The study targets …
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL [Phase 1]
This ClinicalTrials.gov entry reports a Phase 1 study of BAFFR-targeting CAR T cells for relapsed or refractory B-cell non-Hodgkin lymphoma,…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. [Phase 1]
Phase 1 clinical trial evaluating B019 Injection in relapsed or refractory B-cell non-Hodgkin lymphoma; the study status is not yet recruiti…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A prospective Phase 1/2 clinical trial assessing a CD3-CD20 bispecific antibody–based therapy combined with CD19-CAR T cells for relapsed or…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms [Phase 1]
Phase 1 study of CT1195E in relapsed/refractory B-cell neoplasms is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 ) [Phase 1]
Phase 1 clinical trial update for CT1190B in relapsed/refractory B-cell non-Hodgkin lymphoma; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 clinical trial evaluating the combination of Rituximab and Tafasitamab with allogeneic NK cells in relapsed/refractory B-cell non-Ho…